Trial site
Stanford Women's Cancer Center
Palo Alto, California 94304, United StatesNot linked to an institution yet
The trials here
What the 9 trials at this site are about, from their registry records.
- Phase
- Phase 36 trials
- Phase 1/23 trials
- Status
- Recruiting5 trials
- Active, not recruiting4 trials
- Lead sponsor
- Pfizer4 trials
- Eisai Inc.1 trial
- Eli Lilly and Company1 trial
- Gilead Sciences1 trial
- GOG Foundation1 trial
- and 1 more
Running trials
Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804· Phase 3· Eli Lilly and Company· Source
Contact: Kristin Bixel (principal investigator)
Recruiting
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521· Phase 3· Relay Therapeutics, Inc.· Source
Contact: Relay Therapeutics, Inc
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965· Phase 3· Pfizer· Source
Active, not recruiting
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
NCT06966453· Phase 1/2· Pfizer· Source
Active, not recruiting
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637· Phase 3· Pfizer· Source
Active, not recruiting
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441· Phase 3· Gilead Sciences· Source
Recruiting
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
NCT05659381· Phase 3· GOG Foundation· Source
Contact: Amer Karam, MD (principal investigator)
Active, not recruiting
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
NCT05548127· Phase 1/2· Pfizer· Source
Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
NCT04300556· Phase 1/2· Eisai Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error